Featured Research

from universities, journals, and other organizations

Rifamycin Antibiotics Attack Tuberculosis Bacteria With Walls, Not Signals

Date:
August 27, 2008
Source:
Rockefeller University
Summary:
Amid concerns about the rising number of new tuberculosis cases worldwide, researchers have reexamined and disproved a theory that describes how a potent class of antibiotics kills a deadly form of bacteria. The findings not only bring scientists closer to understanding how these antibiotics work but also how the bacteria become resistant to their effects.

Hitting a wall: By binding next to RNA polymerase's active center (pink), the potent class of antibiotics called rifamycins (red and yellow) prevents deadly bacterial RNA from elongating.
Credit: Image courtesy of Rockefeller University

Amid concerns about the rising number of new tuberculosis cases worldwide, researchers led by Rockefeller University’s Seth A. Darst have reexamined and disproved a theory that describes how a potent class of antibiotics kills a deadly form of bacteria. The findings, which will appear soon online in the Proceedings of the National Academy of Sciences, not only bring scientists closer to understanding how these antibiotics work but also how the bacteria become resistant to their effects.

The class of antibiotics, called rifamycins, was developed in the 1950s to combat tuberculosis-causing bacteria. The problem, however, was that the bacteria fought back, quickly developing resistance. And the rate of decline for new tuberculosis cases has begun to slow during the past decade, with more than nine million people across the globe currently afflicted.

Rifamycins kill their prey by binding to RNA polymerase, the enzyme that kicks off gene expression by transcribing DNA to messenger RNA. However, the exact mechanism by which rifamycins interfere with the process had long remained unknown. A breakthrough came in 2001, when Elizabeth Campbell, a research associate in Darst’s Laboratory of Molecular Biophysics, and her colleagues showed that rifamycins bind next to RNA polymerase’s active center such that the rifamycin acts like a wall, physically blocking RNA from elongating. These results supported a steric-occlusion model for rifamycin action that explained — and continues to explain — past findings.

But the newer model, proposed three years ago, describes a very different mechanism. Called the allosteric model, it proposes that rifamycins do, indeed, bind to the enzyme next to the enzyme’s active center, but instead of blocking the elongating RNA molecule, rifamycins transmit a signal to the enzyme’s active center, decreasing a magnesium ion’s ability to bind. Without the magnesium ion, Mg2+, RNA cannot be transcribed.

“It was a beautiful model, but there were parts of it that didn’t add up and those parts directly conflicted with the model published in 2001,” says lead researcher Andrey Feklistov, a postdoc in the Darst lab who conducted the research along with several colleagues at Rockefeller, the Waksman Institute of Microbiology at Rutger’s University and The Public Health Research Institute of New Jersey Medical School.

The steric-occlusion model suggested that the stronger the rifamycin binds — that is, the sturdier the wall — the better it would work to halt transcription. But according to the allosteric model proposed by a team from The Ohio State University, that wasn’t necessarily the case. Even if rifamycins bind strongly, the enzyme could still be rifamycin-resistant due to a blip along the long signaling pathway. “So we did what scientists do,” says Feklistov. “We took another look.”

By testing the same two mutant strains of RNA polymerase that the Ohio team used, ones that had mutations along the proposed signaling pathway, the Darst team found that the mutants were resistant to rifamycin precisely because the antibiotic could not bind tightly to the enzyme. “This suggests that the steric-occlusion model best explains the available biochemical and structural evidence that has been published,” says Feklistov. Moreover, the Darst team found that rifamycins have no effect on metal ion binding to the active center, in direct contradiction to the allosteric model.

Understanding the mechanism by which rifamycins kill bacteria allows scientists to better understand how the tuberculosis-causing bacteria develop resistance to the antibiotics — and develop drugs to combat this effect. “At this stage,” says Feklistov, “any evidence, positive or negative, will help focus our attention toward this goal.”


Story Source:

The above story is based on materials provided by Rockefeller University. Note: Materials may be edited for content and length.


Cite This Page:

Rockefeller University. "Rifamycin Antibiotics Attack Tuberculosis Bacteria With Walls, Not Signals." ScienceDaily. ScienceDaily, 27 August 2008. <www.sciencedaily.com/releases/2008/08/080825110423.htm>.
Rockefeller University. (2008, August 27). Rifamycin Antibiotics Attack Tuberculosis Bacteria With Walls, Not Signals. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/08/080825110423.htm
Rockefeller University. "Rifamycin Antibiotics Attack Tuberculosis Bacteria With Walls, Not Signals." ScienceDaily. www.sciencedaily.com/releases/2008/08/080825110423.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins